Exact Mass: 405.2276972
Exact Mass Matches: 405.2276972
Found 500 metabolites which its exact mass value is equals to given mass value 405.2276972
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Clomifene
C26H28ClNO (405.18593080000005)
Clomifene is only found in individuals that have used or taken this drug. It is a triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. [PubChem]Clomifene has both estrogenic and anti-estrogenic properties, but its precise mechanism of action has not been determined. Clomifene appears to stumulate the release of gonadotropins, follicle-stimulating hormone (FSH), and leuteinizing hormone (LH), which leads to the development and maturation of ovarian follicle, ovulation, and subsequent development and function of the coprus luteum, thus resulting in pregnancy. Gonadotropin release may result from direct stimulation of the hypothalamic-pituitary axis or from a decreased inhibitory influence of estrogens on the hypothalamic-pituitary axis by competing with the endogenous estrogens of the uterus, pituitary, or hypothalamus. Clomifene has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function. G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03G - Gonadotropins and other ovulation stimulants > G03GB - Ovulation stimulants, synthetic D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D012102 - Reproductive Control Agents > D005299 - Fertility Agents C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Toremifene
C26H28ClNO (405.18593080000005)
Toremifene is only found in individuals that have used or taken this drug. It is a first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors. L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BA - Anti-estrogens D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Astromicin
C17H35N5O6 (405.25872100000004)
An amino cyclitol glycoside that is L-chiro-inositol in which the hydroxy groups at positions 1, 4, and 6 are replaced by aminoacetyl)methylamino, amino, and methoxy groups, respectively, and in which the hydroxy group at position 3 is converted to the corresponding 2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranoside. The major component of fortimicin, obtained from Micromonospora olivasterospora. It is administered (as the sulfate salt) by intramuscular injection or intravenous infusion for the treatment of severe systemic infections due to sensitive Gram-negative organisms. C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic
Lisinopril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
Lisinopril
One of the Angiotensin-converting enzyme inhibitors (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. -- Pubchem; Lisinopril is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure and heart attacks. Historically, lisinopril was the third ACE inhibitor, after captopril and enalapril that was introduced into therapy in early 1990s . Lisinopril has a number of properties that distinguish it from other ACE inhibitors: it is hydrophilic, has long half life and tissue penetration and is not metabolized by the liver. -- Wikipedia; Lisinopril is solely excreted in urine in the unchanged form. Elimination of the drug depends on glomerular filtration and tubular excretion. Rate of lisinopril elimination decreases with old age and kidney or heart failure. There is a relation between creatinine and lisinopril clearance. With prolonged therapy dose reduction can be necessary to avoid accumulation. -- Wikipedia [HMDB] One of the Angiotensin-converting enzyme inhibitors (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. -- Pubchem; Lisinopril is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure and heart attacks. Historically, lisinopril was the third ACE inhibitor, after captopril and enalapril that was introduced into therapy in early 1990s. Lisinopril has a number of properties that distinguish it from other ACE inhibitors: it is hydrophilic, has long half life and tissue penetration and is not metabolized by the liver. -- Wikipedia; Lisinopril is solely excreted in urine in the unchanged form. Elimination of the drug depends on glomerular filtration and tubular excretion. Rate of lisinopril elimination decreases with old age and kidney or heart failure. There is a relation between creatinine and lisinopril clearance. With prolonged therapy dose reduction can be necessary to avoid accumulation. -- Wikipedia.
Imidapril
C20H27N3O6 (405.18997620000005)
Imidapril, also known as Tanatril (trade name), belongs to a class of long-acting, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitors (PMID: 12177688). It is a prodrug that is widely used in the treatment of mild to moderate essential hypertension (PMID: 17547476). A prodrug is a drug that must be metabolized in the body (via the gut or the liver) to become active. Imidapril is also prescribed to treat chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy (PMID: 12177688, 17094051). It functions through preventing angiotensin II formation, via inhibition of the angiotensin-converting enzyme (ACE), that results in reduction of peripheral resistance and a reduction in systemic blood pressure (BP) (PMID: 17547476). Imidapril is only found in individuals that have used or taken this drug. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
N-Eicosapentaenoyl Cysteine
C23H35NO3S (405.2337520000001)
N-eicosapentaenoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
4-Oxofenretinide
2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
C26H28ClNO (405.18593080000005)
Astromicin
C17H35N5O6 (405.25872100000004)
Cypridina luciferin
Febarbamate
C20H27N3O6 (405.18997620000005)
M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents > M03BA - Carbamic acid esters C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
N-(4-Methoxyphenyl)-all-trans-retinamide
Nifekalant
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
trequinsin
C24H27N3O3 (405.20523120000007)
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
3-dehydrocholate
3-dehydrocholate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 3-dehydrocholate can be found in a number of food items such as kale, cucurbita (gourd), atlantic herring, and spearmint, which makes 3-dehydrocholate a potential biomarker for the consumption of these food products. Dehydrocholic acid is a synthetic bile acid, manufactured by the oxidation of cholic acid. It acts as a hydrocholeretic, increasing bile output to clear increased bile acid load .
3-[2-(1,1-dimethyl-allyl)-5-(3,3-dimethyl-oxiranylmethyl)-indol-3-ylmethylene]-6-methylene-piperazine-2,5-dione|Isoechinulin C|isoechinulin-C
C24H27N3O3 (405.20523120000007)
nifekalant
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C93038 - Cation Channel Blocker
Hydroxy-roquefortine C
C22H23N5O3 (405.18008080000004)
CONFIDENCE Penicillium bissettii
(+/-)-celallocinnine|2-phenyl-9-(3-phenyl-acryloyl)-1,5,9-triaza-cyclotridecan-4-one|caesalpinine C|celallocinine|Celallocinnin|Celallocinnine
ancistrotanzanine A|ancistrotectorines D
C25H27NO4 (405.19399820000007)
(3E,5aS,10bR)-6,10b,11,11a-tetrahydro-11a-hydroxy-3-(1H-imidazol-5-ylmethylidene)-10b-(2-methylbut-3-en-2-yl)-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione|16-hydroxyroquefortine C
C22H23N5O3 (405.18008080000004)
(+/-)-dihydroperiphylline|4-phenyl-9-(3-phenyl-acryloyl)-1,5,9-triaza-cyclotridecan-2-one|Dihydroperiphyllin|Dihydroperiphylline
(E,E)-Maytenine|Maytenin (1)|maytenine|N1,N8-dicinnamoyl spermidine
(S)-Cypridina luciferin|Cypridina luciferin|[3-(2-sec-butyl-6-indol-3-yl-3-oxo-3,7-dihydro-imidazo[1,2-a]pyrazin-8-yl)-propyl]-guanidine|{3-[2((S)-sec-Butyl)-6-indol-3-yl-3-oxo-3,7-dihydro-imidazo[1,2-a]pyrazin-8-yl]-propyl}-guanidin|{3-[2((S)-sec-butyl)-6-indol-3-yl-3-oxo-3,7-dihydro-imidazo[1,2-a]pyrazin-8-yl]-propyl}-guanidine
(S,3Z)-3-((1,7-dihydro-7,7-dimethyl-2-(2-methylbut-3-en-2-yl)pyrano[2,3-g]indol-3-yl)methylene)-6-methylpiperazine-2,5-dione|talathermophilin B
C24H27N3O3 (405.20523120000007)
22alpha,23alpha-epoxy-10-epi-solanida-1,4,9-trien-3-one
Toremifene
C26H28ClNO (405.18593080000005)
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BA - Anti-estrogens D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Febarbamate
C20H27N3O6 (405.18997620000005)
M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents > M03BA - Carbamic acid esters C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
Imidapril
C20H27N3O6 (405.18997620000005)
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Ala Cys Gly Arg
Ala Cys Arg Gly
Ala Gly Cys Arg
Ala Gly Lys Met
C16H31N5O5S (405.20457960000005)
Ala Gly Met Lys
C16H31N5O5S (405.20457960000005)
Ala Gly Arg Cys
Ala Lys Gly Met
C16H31N5O5S (405.20457960000005)
Ala Lys Met Gly
C16H31N5O5S (405.20457960000005)
Ala Lys Ser Thr
Ala Lys Thr Ser
Ala Met Gly Lys
C16H31N5O5S (405.20457960000005)
Ala Met Lys Gly
C16H31N5O5S (405.20457960000005)
Ala Asn Thr Thr
C15H27N5O8 (405.18595419999997)
Ala Gln Ser Thr
C15H27N5O8 (405.18595419999997)
Ala Gln Thr Ser
C15H27N5O8 (405.18595419999997)
Ala Arg Cys Gly
Ala Arg Gly Cys
Ala Ser Lys Thr
Ala Ser Gln Thr
C15H27N5O8 (405.18595419999997)
Ala Ser Thr Lys
Ala Ser Thr Gln
C15H27N5O8 (405.18595419999997)
Ala Thr Lys Ser
Ala Thr Asn Thr
C15H27N5O8 (405.18595419999997)
Ala Thr Gln Ser
C15H27N5O8 (405.18595419999997)
Ala Thr Ser Lys
Ala Thr Ser Gln
C15H27N5O8 (405.18595419999997)
Ala Thr Thr Asn
C15H27N5O8 (405.18595419999997)
Cys Ala Gly Arg
Cys Ala Arg Gly
Cys Gly Ala Arg
Cys Gly Lys Val
C16H31N5O5S (405.20457960000005)
Cys Gly Arg Ala
Cys Gly Val Lys
C16H31N5O5S (405.20457960000005)
Cys Lys Gly Val
C16H31N5O5S (405.20457960000005)
Cys Lys Val Gly
C16H31N5O5S (405.20457960000005)
Cys Arg Ala Gly
Cys Arg Gly Ala
Cys Val Gly Lys
C16H31N5O5S (405.20457960000005)
Cys Val Lys Gly
C16H31N5O5S (405.20457960000005)
Asp Gly Lys Ser
C15H27N5O8 (405.18595419999997)
Asp Gly Ser Lys
C15H27N5O8 (405.18595419999997)
Asp Lys Gly Ser
C15H27N5O8 (405.18595419999997)
Asp Lys Ser Gly
C15H27N5O8 (405.18595419999997)
Asp Ser Gly Lys
C15H27N5O8 (405.18595419999997)
Asp Ser Lys Gly
C15H27N5O8 (405.18595419999997)
Gly Ala Cys Arg
Gly Ala Lys Met
C16H31N5O5S (405.20457960000005)
Gly Ala Met Lys
C16H31N5O5S (405.20457960000005)
Gly Ala Arg Cys
Gly Cys Ala Arg
Gly Cys Lys Val
C16H31N5O5S (405.20457960000005)
Gly Cys Arg Ala
Gly Cys Val Lys
C16H31N5O5S (405.20457960000005)
Gly Asp Lys Ser
C15H27N5O8 (405.18595419999997)
Gly Asp Ser Lys
C15H27N5O8 (405.18595419999997)
Gly Lys Ala Met
C16H31N5O5S (405.20457960000005)
Gly Lys Cys Val
C16H31N5O5S (405.20457960000005)
Gly Lys Asp Ser
C15H27N5O8 (405.18595419999997)
Gly Lys Met Ala
C16H31N5O5S (405.20457960000005)
Gly Lys Ser Asp
C15H27N5O8 (405.18595419999997)
Gly Lys Thr Thr
Gly Lys Val Cys
C16H31N5O5S (405.20457960000005)
Gly Met Ala Lys
C16H31N5O5S (405.20457960000005)
Gly Met Lys Ala
C16H31N5O5S (405.20457960000005)
Gly Gln Thr Thr
C15H27N5O8 (405.18595419999997)
Gly Arg Ala Cys
Gly Arg Cys Ala
Gly Arg Ser Ser
Gly Ser Asp Lys
C15H27N5O8 (405.18595419999997)
Gly Ser Lys Asp
C15H27N5O8 (405.18595419999997)
Gly Ser Arg Ser
Gly Ser Ser Arg
Gly Thr Lys Thr
Gly Thr Gln Thr
C15H27N5O8 (405.18595419999997)
Gly Thr Thr Lys
Gly Thr Thr Gln
C15H27N5O8 (405.18595419999997)
Gly Val Cys Lys
C16H31N5O5S (405.20457960000005)
Gly Val Lys Cys
C16H31N5O5S (405.20457960000005)
Lys Ala Gly Met
C16H31N5O5S (405.20457960000005)
Lys Ala Met Gly
C16H31N5O5S (405.20457960000005)
Lys Ala Ser Thr
Lys Ala Thr Ser
Lys Cys Gly Val
C16H31N5O5S (405.20457960000005)
Lys Cys Val Gly
C16H31N5O5S (405.20457960000005)
Lys Asp Gly Ser
C15H27N5O8 (405.18595419999997)
Lys Asp Ser Gly
C15H27N5O8 (405.18595419999997)
Lys Gly Ala Met
C16H31N5O5S (405.20457960000005)
Lys Gly Cys Val
C16H31N5O5S (405.20457960000005)
Lys Gly Asp Ser
C15H27N5O8 (405.18595419999997)
Lys Gly Met Ala
C16H31N5O5S (405.20457960000005)
Lys Gly Ser Asp
C15H27N5O8 (405.18595419999997)
Lys Gly Thr Thr
Lys Gly Val Cys
C16H31N5O5S (405.20457960000005)
Lys Met Ala Gly
C16H31N5O5S (405.20457960000005)
Lys Met Gly Ala
C16H31N5O5S (405.20457960000005)
Lys Ser Ala Thr
Lys Ser Asp Gly
C15H27N5O8 (405.18595419999997)
Lys Ser Gly Asp
C15H27N5O8 (405.18595419999997)
Lys Ser Thr Ala
Lys Thr Ala Ser
Lys Thr Gly Thr
Lys Thr Ser Ala
Lys Thr Thr Gly
Lys Val Cys Gly
C16H31N5O5S (405.20457960000005)
Lys Val Gly Cys
C16H31N5O5S (405.20457960000005)
Met Ala Gly Lys
C16H31N5O5S (405.20457960000005)
Met Ala Lys Gly
C16H31N5O5S (405.20457960000005)
Met Gly Ala Lys
C16H31N5O5S (405.20457960000005)
Met Gly Lys Ala
C16H31N5O5S (405.20457960000005)
Met Lys Ala Gly
C16H31N5O5S (405.20457960000005)
Met Lys Gly Ala
C16H31N5O5S (405.20457960000005)
Asn Ala Thr Thr
C15H27N5O8 (405.18595419999997)
Asn Ser Ser Val
C15H27N5O8 (405.18595419999997)
Asn Ser Val Ser
C15H27N5O8 (405.18595419999997)
Asn Thr Ala Thr
C15H27N5O8 (405.18595419999997)
Asn Thr Thr Ala
C15H27N5O8 (405.18595419999997)
Asn Val Ser Ser
C15H27N5O8 (405.18595419999997)
Gln Ala Ser Thr
C15H27N5O8 (405.18595419999997)
Gln Ala Thr Ser
C15H27N5O8 (405.18595419999997)
Gln Gly Thr Thr
C15H27N5O8 (405.18595419999997)
Gln Ser Ala Thr
C15H27N5O8 (405.18595419999997)
Gln Ser Thr Ala
C15H27N5O8 (405.18595419999997)
Gln Thr Ala Ser
C15H27N5O8 (405.18595419999997)
Gln Thr Gly Thr
C15H27N5O8 (405.18595419999997)
Gln Thr Ser Ala
C15H27N5O8 (405.18595419999997)
Gln Thr Thr Gly
C15H27N5O8 (405.18595419999997)
Arg Ala Cys Gly
Arg Ala Gly Cys
Arg Cys Ala Gly
Arg Cys Gly Ala
Arg Gly Ala Cys
Arg Gly Cys Ala
Arg Gly Ser Ser
Arg Ser Gly Ser
Arg Ser Ser Gly
Ser Ala Lys Thr
Ser Ala Gln Thr
C15H27N5O8 (405.18595419999997)
Ser Ala Thr Lys
Ser Ala Thr Gln
C15H27N5O8 (405.18595419999997)
Ser Asp Gly Lys
C15H27N5O8 (405.18595419999997)
Ser Asp Lys Gly
C15H27N5O8 (405.18595419999997)
Ser Gly Asp Lys
C15H27N5O8 (405.18595419999997)
Ser Gly Lys Asp
C15H27N5O8 (405.18595419999997)
Ser Gly Arg Ser
Ser Gly Ser Arg
Ser Lys Ala Thr
Ser Lys Asp Gly
C15H27N5O8 (405.18595419999997)
Ser Lys Gly Asp
C15H27N5O8 (405.18595419999997)
Ser Lys Thr Ala
Ser Asn Ser Val
C15H27N5O8 (405.18595419999997)
Ser Asn Val Ser
C15H27N5O8 (405.18595419999997)
Ser Gln Ala Thr
C15H27N5O8 (405.18595419999997)
Ser Gln Thr Ala
C15H27N5O8 (405.18595419999997)
Ser Arg Gly Ser
Ser Arg Ser Gly
Ser Ser Gly Arg
Ser Ser Asn Val
C15H27N5O8 (405.18595419999997)
Ser Ser Arg Gly
Ser Ser Val Asn
C15H27N5O8 (405.18595419999997)
Ser Thr Ala Lys
Ser Thr Ala Gln
C15H27N5O8 (405.18595419999997)
Ser Thr Lys Ala
Ser Thr Gln Ala
C15H27N5O8 (405.18595419999997)
Ser Val Asn Ser
C15H27N5O8 (405.18595419999997)
Ser Val Ser Asn
C15H27N5O8 (405.18595419999997)
Thr Ala Lys Ser
Thr Ala Asn Thr
C15H27N5O8 (405.18595419999997)
Thr Ala Gln Ser
C15H27N5O8 (405.18595419999997)
Thr Ala Ser Lys
Thr Ala Ser Gln
C15H27N5O8 (405.18595419999997)
Thr Ala Thr Asn
C15H27N5O8 (405.18595419999997)
Thr Gly Lys Thr
Thr Gly Gln Thr
C15H27N5O8 (405.18595419999997)
Thr Gly Thr Lys
Thr Gly Thr Gln
C15H27N5O8 (405.18595419999997)
Thr Lys Ala Ser
Thr Lys Gly Thr
Thr Lys Ser Ala
Thr Lys Thr Gly
Thr Asn Ala Thr
C15H27N5O8 (405.18595419999997)
Thr Asn Thr Ala
C15H27N5O8 (405.18595419999997)
Thr Gln Ala Ser
C15H27N5O8 (405.18595419999997)
Thr Gln Gly Thr
C15H27N5O8 (405.18595419999997)
Thr Gln Ser Ala
C15H27N5O8 (405.18595419999997)
Thr Gln Thr Gly
C15H27N5O8 (405.18595419999997)
Thr Ser Ala Lys
Thr Ser Ala Gln
C15H27N5O8 (405.18595419999997)
Thr Ser Lys Ala
Thr Ser Gln Ala
C15H27N5O8 (405.18595419999997)
Thr Thr Ala Asn
C15H27N5O8 (405.18595419999997)
Thr Thr Gly Lys
Thr Thr Gly Gln
C15H27N5O8 (405.18595419999997)
Thr Thr Lys Gly
Thr Thr Asn Ala
C15H27N5O8 (405.18595419999997)
Thr Thr Gln Gly
C15H27N5O8 (405.18595419999997)
Val Cys Gly Lys
C16H31N5O5S (405.20457960000005)
Val Cys Lys Gly
C16H31N5O5S (405.20457960000005)
Val Gly Cys Lys
C16H31N5O5S (405.20457960000005)
Val Gly Lys Cys
C16H31N5O5S (405.20457960000005)
Val Lys Cys Gly
C16H31N5O5S (405.20457960000005)
Val Lys Gly Cys
C16H31N5O5S (405.20457960000005)
Val Asn Ser Ser
C15H27N5O8 (405.18595419999997)
Val Ser Asn Ser
C15H27N5O8 (405.18595419999997)
Val Ser Ser Asn
C15H27N5O8 (405.18595419999997)
Tetranor PGE1 Taurine
C18H31NO7S (405.18211360000004)
1,2-Diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]butane-1,4-diol
1-[4-(1-ADAMANTYL)PHENOXY]-3-PIPERIDINOPROPAN-2-OL HYDROCHLORIDE
C24H36ClNO2 (405.24344260000004)
Urea, N-cyclohexyl-N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(3-pyridinylmethyl)- (9CI)
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoate
potassium: 1,2-diethenylbenzene: 1-ethenyl-2-ethyl-benzene: styrene
4-Oxofenretinide
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
2(S)-ACETYLTHIO-BENZENEPROPANOIC ACID N-CYCLOHEXYLCYCLOHEXANAMINE
C23H35NO3S (405.2337520000001)
(S)-METHYL 2-((TERT-BUTOXYCARBONYL)AMINO)-3-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PROPANOATE
Bencyclane fumarate
C23H35NO5 (405.25151000000005)
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
1H-Indole-1-carboxylic acid, 2-borono-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, 1-(1,1-dimethylethyl) ester (9CI)
1H-Indole-1-carboxylic acid, 2-borono-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, 1,1-dimethylethyl ester
4-(N-Ethyl-N-benzyl)amino benzoaldehyde-1,1-diphenylhydrazone
2(r)-acetylthio-benzenepropanoic acid n-cyclohexylcyclohexanamine
C23H35NO3S (405.2337520000001)
Adoprazine
Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics[1].
2-Chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[1-(2-hydroxyethyl)-5 -methyl-1H-pyrazol-3-yl]benzamide
C21H28ClN3O3 (405.1819088000001)
Terbogrel
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent C471 - Enzyme Inhibitor
DIETHYL 1,4-DIHYDRO-2,6-DIMETHYL-1,4-DIPHENYL-3,5-PYRIDINEDICARBOXYLATE
C25H27NO4 (405.19399820000007)
8-Cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
3-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy-benzoic acid methyl ester hydrochloride (1:1)
C23H31NO3.HCl (405.20705920000006)
Carbamic acid, N-[(1S)-1-[[[(1S)-1-(hydroxymethyl)-2-(2-oxo-3-pyrrolidinyl)ethyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester
N-Fmoc-2-amino-2-(3-butenyl)hex-5-enoic acid
C25H27NO4 (405.19399820000007)
1-isopropyl-1-(2-methyl-1H-benzo[d]imidazole-6-carbonyl)-4,6-dihydrospiro[indazole-5,4-piperidin]-7(1H)-one
PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 27.0, 33.0, 23.5 and 50.4 nM for ACC1 (human), ACC2 (human), ACC1 (rat), ACC2 (rat), respectively.
N-(4-Methoxyphenyl)-all-trans-retinamide
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
Celacinnine
A spermidine alkaloid that is isolated from Maytenus heterophylla and Maytenus senegalensis.
2-[trans-(4-Aminocyclohexyl)amino]-6-(benzyl-amino)-9-cyclopentylpurine
N-(1-Isopropylpiperidin-4-YL)-1-(3-methoxybenzyl)-1H-indole-2-carboxamide
N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide
C21H35N5O3 (405.27397600000006)
Clomifene
C26H28ClNO (405.18593080000005)
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03G - Gonadotropins and other ovulation stimulants > G03GB - Ovulation stimulants, synthetic D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D012102 - Reproductive Control Agents > D005299 - Fertility Agents C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor
3alpha,7alpha-Dihydroxy-12-oxo-5beta-cholanate
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
7alpha,12alpha-Dihydroxy-3-oxo-5beta-cholan-24-Oate
A bile acid anion that is the conjugate base of 7alpha,12alpha-dihydroxy-3-oxo-5beta-cholan-24-oic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine
C26H28ClNO (405.18593080000005)
(Z)-6-[3-[(N-tert-butyl-N-cyanocarbamimidoyl)amino]phenyl]-6-pyridin-3-ylhex-5-enoic acid
Ancistrotanzanine A
C25H27NO4 (405.19399820000007)
An isoquinoline alkaloid that is (3S)-6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinoline substituted by a 1-hydroxy-8-methoxy-3-methylnaphthalen-2-yl group at position 5. It is isolated from the leaves of Ancistrocladus tanzaniensis and exhibits antiplasmodial, antileishmanial and antitrypanocidal activities.
1-[4-(9-Benzylfluoren-9-yl)but-2-ynyl]azepane
D002317 - Cardiovascular Agents > D026902 - Potassium Channel Blockers D049990 - Membrane Transport Modulators
22alpha,23alpha-Epoxy-solanida-1,4,9-trien-3-one
A natural product found in Solanum campaniforme.
(2S)-Hydroxy-(11S,12R)-dihydrostemofoline, (rel)-
A natural product found in Stemona aphylla.
Oxystemokerrine
A natural product found particularly in Stemona and Stemona curtisii.
Talathermophilins B
C24H27N3O3 (405.20523120000007)
A natural product found in Talaromyces thermophilus and Talaromyces thermophilus.
2-[[4-amino-6-(2-methylanilino)-1,3,5-triazin-2-yl]methyl-methylamino]-N-(2-ethylphenyl)acetamide
4-[4-[(1-Cyclopentyl-5-tetrazolyl)-pyridin-4-ylmethyl]-1-piperazinyl]phenol
2-[(2-hydroxy-1-naphthalenyl)methyl-methylamino]-N-[4-(4-morpholinyl)phenyl]acetamide
C24H27N3O3 (405.20523120000007)
N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]cyclohexanecarboxamide
4-[[3-(Diethylamino)propylamino]methylidene]-2-(2,6-dimethylphenyl)isoquinoline-1,3-dione
4-[(1-cyclopentyl-5-tetrazolyl)-(3,4-dihydro-1H-isoquinolin-2-yl)methyl]-2-methoxyphenol
N-[2-(3,4-diethoxyphenyl)ethyl]-4-phenoxybenzamide
C25H27NO4 (405.19399820000007)
2-(4-Chlorophenyl)-3-(4-fluorophenyl)-1-(4-morpholinyl)-3-heptanol
1-[(2S,3S,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-(3-methoxyphenyl)urea
1-[(2S,3R,6S)-6-[2-[4-(3-fluorophenyl)triazol-1-yl]ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3S,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3S,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-(2-oxo-2-piperidin-1-ylethyl)oxan-3-yl]-3-(3-methoxyphenyl)urea
1-[(2S,3R,6R)-2-(hydroxymethyl)-6-(2-oxo-2-piperidin-1-ylethyl)oxan-3-yl]-3-(3-methoxyphenyl)urea
N-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
1-[(2S,3R,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3R,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-(3-methoxyphenyl)urea
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-(3-methoxyphenyl)urea
1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-(3-methoxyphenyl)urea
N-[2-[(2R,5S,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
N-[2-[(2S,5S,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
1-(2-fluorophenyl)-3-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-(2-fluorophenyl)-3-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-(2-fluorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
C20H27N3O6 (405.18997620000005)
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
C20H27N3O6 (405.18997620000005)
1-[(2R,3R,6S)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3S,6S)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3S,6S)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(8R,9S,10S)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
1-[(8R,9S,10R)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
1-[(8R,9R,10S)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
[(8S,9R,10S)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10R)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C22H35N3O4 (405.26274300000006)
1-[(2R,3S,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3R,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propylurea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-(3-methoxyphenyl)urea
1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-(3-methoxyphenyl)urea
N-[2-[(2S,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
N-[2-[(2R,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
N-[2-[(2R,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
N-[2-[(2R,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
N-[2-[(2S,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
N-[2-[(2S,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
C20H27N3O6 (405.18997620000005)
1-(2-fluorophenyl)-3-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-(2-fluorophenyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-(2-fluorophenyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-(2-fluorophenyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-(2-fluorophenyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-propyl-1-triazolyl)ethyl]-3-oxanyl]urea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
C20H27N3O6 (405.18997620000005)
1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
C20H27N3O6 (405.18997620000005)
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
C20H27N3O6 (405.18997620000005)
1-[(2S,3R,6S)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3S,6R)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3R,6R)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(2R,3R,6R)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(2S,3S,6R)-6-[2-[4-(4-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-propan-2-ylurea
C20H28FN5O3 (405.21760700000004)
1-[(8S,9R,10R)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
1-[(8S,9R,10S)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
1-[(8R,9R,10R)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
1-[(8S,9S,10S)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
1-[(8S,9S,10R)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-pyridin-3-ylethanone
[(8R,9S,10R)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10S)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9R,10R)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-phenylethanone
C24H27N3O3 (405.20523120000007)
1-[(1S)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-phenylethanone
C24H27N3O3 (405.20523120000007)
[(1R)-1-(hydroxymethyl)-7-methoxy-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone
C24H27N3O3 (405.20523120000007)
[(1S)-1-(hydroxymethyl)-7-methoxy-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone
C24H27N3O3 (405.20523120000007)
(E)-2-(decanoylamino)-3-hydroxydec-4-ene-1-sulfonic acid
C20H39NO5S (405.25488040000005)
trequinsin
C24H27N3O3 (405.20523120000007)
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
SPHP(20:2)
C20H40NO5P (405.2643960000001)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved